Shares of Vanda Pharmaceuticals (VNDA.US) experienced a significant uptick on Wednesday. At the time of writing, the stock had surged more than 32%, reaching $9.33 per share. The price movement follows the company's announcement that its new drug, Nereus, has received approval from the U.S. Food and Drug Administration (FDA) for the prevention of motion-induced vomiting. Vanda stated that the FDA's approval decision was based on the results from three clinical studies. These trials compared the treatment group against a placebo group, evaluating the incidence of vomiting. The data indicated that Nereus achieved a "significant reduction" in vomiting episodes and demonstrated a "favorable safety profile" in short-term, acute-use scenarios. Vanda announced its plan to officially launch Nereus in the coming months. The market widely perceives the drug's approval as potentially creating a new avenue for commercial growth for the company, while also further enriching its product portfolio in the central nervous system and related therapeutic areas.